◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound WATCH-LIST MEDIUM

Yohimbine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict WATCH-LIST MEDIUM

"Yohimbine is a real pharmacological tool with a narrow, situational use case — fasted-state pre-cardio fat oxidation in already-lean lifters trying to mobilize the last 1-3% body fat in an α2-rich depot. The McCarty 2002 mechanism + Galitzky 1988 + Ostojic 2006 (lean soccer players) literature supports the use. BUT — this user is a 20yo MMA athlete with a brain-priority frame, anxiety-baseline that's modest but trackable, and a chronotype migration in progress. Yohimbine's anxiogenic ceiling is sharp and dose-dependent (Charney 1984: it is *literally the lab panic-challenge agent*); it stacks badly with caffeine and modafinil; CYP2D6 substrate status means plasma levels are unpredictable until 23andMe lands (~June 2026). The fat-loss case for a 20yo combat athlete who is *already lean and already doing fasted morning cardio* is weak — the marginal body-comp benefit is small and the anxiety + sleep + cardiovascular costs are not worth it in a brain-priority frame. Verdict reopens narrowly to OPTIONAL ADD if (a) a specific contest cut requires last-3% mobilization, (b) CYP2D6 phenotype is normal/extensive (not PM), (c) anxiety baseline is low, (d) total caffeine/sympathomimetic load that day is zero."

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20-30, brain-priority, MMA athlete, modest anxiety baseline, chronotype migration in progress (this archetype)
    WATCH-LIST

    MEDIUM confidence. Not at this life stage and not for this archetype. The fat-loss case is weak (already lean, already doing fasted morning cardio without yohimbine adds 1-3% body fat at most over 3 weeks per Ostojic 2006); the anxiety + cardiovascular costs are real; the CYP2D6 unknown is load-bearing; the chronotype migration cannot afford the sympathetic + sleep architecture cost. Verdict reopens narrowly for a specific contest cut + CYP2D6 EM result + zero stacked sympathomimetics that day + low-anxiety baseline confirmed.

  • 30-50, executive, recreationally lean
    OPTIONAL

    ADD, situational. Fasted-cardio body-comp tool. Modest evidence (Ostojic-style). Manage CV load + anxiety carefully. Skip if stacked with caffeine, modafinil, or other stims.

  • 50+, longevity-focus
    SKIP

    Cardiovascular load profile wrong; longevity benefit unestablished; better tools for body comp at this life stage (GLP-1 agonists, metformin, training prescription).

  • Anxiety-prone
    HARD AVOID

    This is *the* lab panic-challenge molecule. The dose-response curve is steep. Even 5 mg can trigger panic-spectrum symptoms in panic-prone users.

  • Already-lean lifter doing fasted cardio (the actual indication)
    OPTIONAL ADD

    5-10 mg fasted AM 30-45 min pre-cardio, 4-8 week block, 2-week washout. Track BP/HR.

  • Untrained, overweight
    SKIP

    Diet + training prescription are vastly more important than yohimbine for early body-comp work. The α2 stubborn-fat advantage doesn't apply until you're already lean.

  • High athletic load, tested status (combat sports)
    NOT

    BANNED (not on WADA list). But sympathetic load + sleep cost + anxiety risk in a fight camp = wrong tool for the job.

  • Sleep-disordered
    SKIP

    Will worsen sleep architecture even with AM dosing.

  • Recovery-focused (post-injury)
    SKIP

    Catabolic-leaning, sympathetic load — opposite of what recovery needs.

  • Strength/anabolic-focused
    SKIP

    No muscle-building benefit; modest CV load.

  • ED, pre-Viagra-era management (PDE5i unavailable / contraindicated)
    OPTIONAL

    5.4 mg tid x 6-10 weeks. Modern ED management overwhelmingly prefers sildenafil/tadalafil.

▸ Subjective experience (deep)

Onset: 30-60 min for capsule; faster (~20 min) on empty stomach.

Tmax: 1-2 hours.

At 5 mg, fasted, normal CYP2D6 phenotype:

  • Mild sympathetic activation: HR rises 5-10 bpm, BP +3-7 mmHg systolic.
  • Subtle alertness, sometimes a "cold" or restless feel without strong drive.
  • Slight tingle in extremities; mild GI urgency in some users.
  • Emotional tone neutral-to-slightly-edgy; no euphoria.
  • Cardio capacity unchanged at submax efforts; some users report higher RPE for same workload.

At 10-15 mg, fasted, normal CYP2D6:

  • HR +10-15 bpm, BP +5-10 mmHg systolic.
  • Clear "wired" sensation; can feel "amped" or "edgy" depending on baseline.
  • Mild jaw tension, hand tremor possible.
  • Anxiety-prone users start to feel restlessness, racing thoughts.
  • Lipolytic effect biochemically present but subjectively invisible (you don't "feel fat burning" — you feel sympathetic activation).
  • Fasted cardio session 30-45 min into dose: subjectively normal-to-slightly-harder; HR runs higher than baseline at given pace.

At 20+ mg, anxiety-prone or CYP2D6 PM:

  • Strong sympathetic activation: HR +15-25 bpm, BP +10-15 mmHg systolic.
  • Marked anxiety, racing thoughts, sometimes panic-like sensations (the Charney 1984 phenotype).
  • Tremor, GI distress, jaw clenching.
  • Insomnia even if dosed pre-9 AM.
  • This is the dose range where most ER yohimbine cases occur (often stacked with caffeine).

Honest variability: the dose-response is strongly individual-dependent. The same 10 mg can produce a "barely felt anything" experience in a CYP2D6 EM with low anxiety baseline and a "panic-attack-grade" experience in a PM with moderate baseline anxiety. Without a CYP2D6 result, you're titrating blind.

▸ Tolerance + cycling deep dive
  • Pharmacological tolerance: Modest. α2 receptor density does not rapidly downregulate the way β2 does. Most users describe stable effects across weeks.
  • Behavioral tolerance: Subjective anxiety component sometimes habituates somewhat over 2-3 weeks of regular use.
  • Recommended cycle: Short blocks of 4-8 weeks max, with 2-week washout. Many users do PRN-only (only on cardio days) and never run continuous protocols.
  • Reset: No formal protocol needed; rapid clearance means each dose is essentially a reset. Long-term BP/HR creep should prompt extended washout.
▸ Stacking deep dive

Synergistic with

  • Fasted morning cardio (the protocol's purpose) — the entire evidence base assumes this combination.
  • Electrolytes (Na, Mg) — replenish sweat losses; mitigate orthostatic symptoms.
  • L-tyrosine — theoretically — substrate for ongoing NE synthesis under elevated sympathetic demand. No RCT data; mechanistically reasonable.

Avoid stacking with

  • caffeine, paraxanthine: Cumulative sympathetic load — anxiety + BP + HR + arrhythmia risk superlinear. The combination behind most fat-burner ER visits. If pairing, cap caffeine at 100-150 mg and yohimbine at 5 mg, fasted, AM only.
  • modafinil, armodafinil: Additive HR/BP load + anxiety; both increase sympathetic tone via different mechanisms.
  • Amphetamines (Adderall, Vyvanse, Dexedrine), methylphenidate, methamphetamine: Stacked α + β + sympathomimetic effects. Anxiety, BP spike, arrhythmia risk. Hard avoid.
  • MAOIs (tranylcypromine, phenelzine, isocarboxazid): Hypertensive crisis risk. Absolute contraindication. 14-day washout required.
  • Selegiline >10 mg/day (loses MAO-B selectivity): same MAOI concern at higher doses.
  • Strong CYP2D6 inhibitors: fluoxetine, paroxetine, bupropion, quinidine, ritonavir. Raise yohimbine plasma 5-10x → unpredictable toxicity at standard supplement doses.
  • Tricyclic antidepressants: NE/QT compound risk.
  • Synephrine, ephedrine, DMAA, DMHA pre-workouts: Cumulative sympathomimetic stacking. Hard avoid.
  • Clonidine, guanfacine (α2 agonists): Direct receptor competition. Yohimbine antagonizes their BP-lowering and ADHD-augmenting effects.
  • Sildenafil / tadalafil — mechanistically complementary but historically the modern ED management is PDE5i-alone; stacking yohimbine adds anxiety + CV load without much extra erectile benefit.

Neutral / safe co-administration

  • Most of a typical canonical stack: creatine, beta-alanine, magnesium, NAC, citicoline, DHA, curcumin, vitamin D, K2, l-theanine, l-tryptophan — all neutral.
  • BPC-157, TB-500, peptides — neutral.
  • Rhodiola — theoretical mild antagonism (rhodiola is mild adaptogenic; effect dwarfed by yohimbine).
  • L-theanine — actually useful as anxiety mitigation if yohimbine is used; 200-400 mg co-administered may smooth the edge (mechanism: NMDA / GABA tone; not direct α2-antagonism reversal).
▸ Drug interactions deep dive

Yohimbine's metabolic profile:

  • Primary metabolism: CYP2D6 (Le Corre 1999). Stereoselective. ~7-10% Caucasians are PMs (ultra-low CYP2D6 activity); 1-3% UMs (high activity).
  • 11-hydroxyyohimbine is the major metabolite; partly active.
  • Half-life 0.5-2h in EMs, 6+h in PMs.

Clinically significant interactions:

  1. CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine, terbinafine, ritonavir, cinacalcet, mirabegron): Raise yohimbine plasma 5-10x. Standard 10 mg dose can hit toxic-tier exposure.

  2. CYP2D6 inducers are rare; tobacco modestly induces 2D6 in some studies but effect is small for yohimbine.

  3. MAOIs (non-selective): Hypertensive crisis. Absolute contraindication.

  4. Sympathomimetics: Additive cardiovascular load. See stacking.

  5. Antihypertensives: Yohimbine antagonizes α2 agonist antihypertensives (clonidine, guanfacine). May raise dose-requirement of other antihypertensives via sympathetic activation.

  6. Insulin / oral antihyperglycemics: Yohimbine raises NE-driven gluconeogenesis modestly; rarely clinically significant in non-diabetic users.

  7. Hormonal contraceptives: No direct PK interaction.

▸ Pharmacogenomics

CYP2D6 (rs3892097, rs1065852, rs28371725, rs28371706, others):

  • EM (extensive metabolizer, ~70-80% Caucasians): Standard dosing predictable. 10 mg → expected 5-15 bpm HR rise, 5-10 mmHg BP rise, half-life ~2h.
  • IM (intermediate metabolizer, ~10-15%): Slightly higher exposure; cautious dosing (~50% standard) reasonable.
  • PM (poor metabolizer, ~7-10% Caucasians, higher in Mediterranean / North African populations): Plasma exposure 5-10x higher. Standard 5-10 mg dose can produce panic-grade anxiety + hypertensive episodes. Most yohimbine ER cases involve stacked load + likely PM phenotype. Safe dose may be 1-2.5 mg if used at all.
  • UM (ultrarapid metabolizer, 1-3% Caucasians, higher in Ethiopian / Middle Eastern populations up to 20%): Plasma exposure lower; standard doses may feel "weak"; 15-20 mg may be needed for effect — but anxiety risk still scales.

For this user — pending 23andMe (~June 5-15, 2026): Without CYP2D6 result, can't titrate safely. UM phenotype would mean standard supplement doses are sub-effective; PM phenotype would mean even 5 mg is potentially panic-grade. This is the strongest argument for "wait until June" before any yohimbine consideration.

ADRA2A (rs1800544, rs553668): α2A receptor variants modestly predict NE-system reactivity. Less load-bearing than CYP2D6 for yohimbine specifically.

COMT Val158Met (rs4680): Met/Met (slower cortical DA clearance, "worriers") more anxiety-prone on yohimbine. Val/Val tolerates the NE rise better.

ADORA2A rs5751876: Caffeine-anxiety variant — TT carriers more anxiety-prone with caffeine + yohimbine combination than CC/CT.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC supplement (yohimbine HCl, standardized) Primaforce, NOW, Nutricost, BulkSupplements $15-30 / 100 caps High with standardized HCl product Look for "yohimbine HCl 2.5mg or 5mg per cap" — discrete mg labeling. NSF / USP certification preferred.
OTC yohimbe bark extract (UNSTANDARDIZED) Various herbal brands $10-20 LOW — avoid Yohimbine content varies 100-fold lot-to-lot. Most ER cases trace to these.
Pre-workout / fat-burner blend Various $30-60 LOW — avoid Hidden in proprietary blends. Cumulative dosing impossible to verify.
Pre-Viagra Rx (Yocon, Aphrodyne — historical) Discontinued / very limited US Rx N/A N/A Yocon 5.4mg yohimbine HCl was the original Rx. Has effectively exited the US market.
Compounding pharmacy Various $30-60/mo Medium Some compounding pharmacies will make yohimbine HCl capsules at custom dose with Rx. Not standard.
WADA testing N/A N/A N/A NOT prohibited. Yohimbine is not on the 2026 WADA Prohibited List — usable for tested combat athletes if other risk-management criteria are met.
EU / UK Sale prohibited (UK 2022 onward); Australia Rx-only N/A N/A Increasingly restricted in EU markets. US OTC remains legal.

For this user: Not currently sourcing. Verdict is WATCH-LIST. If contest cut + CYP2D6 EM phenotype + low anxiety baseline ever align, NOW or Primaforce yohimbine HCl 2.5mg/cap is the safe entry — start at 2.5 mg fasted and titrate carefully.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Resting BP + HR — 3-day morning average. Standard yohimbine dose adds 5-15 bpm and 5-10 mmHg systolic; baseline-elevated users should not.
  • GAD-7 / PSS / anxiety VAS — establish baseline before any sympathomimetic load.
  • Body fat % (DXA preferred, BIA acceptable) — only relevant data point for the body-comp use case is delta over time.
  • Sleep tracker (Oura) baseline for 14 nights — REM%, deep%, sleep onset latency, total time.
  • CYP2D6 phenotype (23andMe / pharmacogenomic panel) — the single most useful pre-test data point. Without it, dose titration is blind.
  • CBC, CMP, ALT/AST — rule out hepatic/renal contraindications.
  • Urinalysis + thyroid panel — rule out hyperthyroid (hard contraindication).

During use

  • Pre-dose + 60-min-post-dose HR/BP for the first 3-5 doses. If post-dose HR rises >25 bpm or BP >15 mmHg systolic, abandon.
  • Daily sleep tracking — REM/deep on use-days vs off-days. The subjective-objective disconnect that defines caffeine sleep effects also applies to yohimbine.
  • Weekly anxiety VAS — flag any creep upward even at conservative doses.
  • Body-comp delta (4-week DXA cadence) — only way to verify the lipolytic effect is real for the user.

Post-cycle

  • Resting BP/HR returning to baseline within 1-2 weeks confirms healthy washout.
  • GAD-7 re-check at week 2 post-cycle — ensure no residual anxiety creep.
▸ Controversies / open debates Live debate

1. "Stubborn fat is real and yohimbine is the only tool for it."

  • Partly true. α2-receptor distribution differences between fat depots are documented (Lafontan 1995, Mauriège 1991). The gluteofemoral / lower-abdominal α2 dominance is real. Yohimbine does mobilize these depots at fasted state.
  • Counter-argument: The marginal benefit is small (Ostojic 2006: -2.2% fat mass over 3 weeks) and other interventions (HIIT, cold exposure, training pre-meal, contest-prep diet discipline) cover most of the same ground without the anxiety + CV cost. For users >12% body fat, the "stubborn fat" framing is mostly aspirational marketing — they're not at the stage where α2-receptor depot specificity is the limiting factor.

2. "The anxiety risk is overstated; real users handle it fine."

  • Partly true. Most healthy users at 5-10 mg fasted AM tolerate it. Dose-response is steep beyond that.
  • Counter-argument: The Charney 1984 panic-provocation phenotype is not limited to panic-disorder patients — it shifts the response curve, but healthy controls also panic at high enough doses. The combination of stacked stimulants + non-AM dosing + fed state + slow metabolizer phenotype produces the toxic load. The overall safety profile is acceptable for the narrow use case but has more dimensions of failure than most supplement marketing acknowledges.

3. "Fed-state yohimbine still works — McCarty's hypothesis is overrated."

  • Mostly false. Subsequent fat-cell studies (Berlan 1991; Lafontan 1995) confirmed insulin's PDE3B-mediated suppression of cAMP downstream of α2 blockade. Fed-state lipolysis effect is much smaller, sometimes absent.
  • Practical: the McCarty 2002 framing is the load-bearing hypothesis for any meaningful body-comp use. Fed-state yohimbine retains the anxiogenic and CV load without the lipolytic benefit — a strictly worse trade-off.

4. "Yohimbe bark extract is just as good as standardized yohimbine HCl."

  • False and dangerous. Yohimbe bark has 0.1-15% w/w yohimbine across lots — a 500 mg bark capsule can contain 0.5-75 mg yohimbine. Most ER yohimbine cases trace to bark products dosed by capsule count rather than mg of alkaloid.

5. "Use yohimbine for ED to avoid PDE5i."

  • Mostly outdated. Effect size of yohimbine in ED is real but modest (Ernst 1998 OR ~3.85). Sildenafil/tadalafil have much larger effect sizes (~0.6-0.7 SMD on IIEF-5) and cleaner side-effect profiles. The legacy use case has narrowed to PDE5i-intolerant or PDE5i-contraindicated patients.

6. "Rauwolscine (α-yohimbine) is better than yohimbine."

  • More potent at α2, similar mechanism, similar anxiety profile. Marketed in pre-workouts as a "selective" alternative. Quality control is even worse than yohimbine HCl. Not a meaningful upgrade for typical use.
▸ Verdict change log
  • 2026-05-10 — Initial verdict: WATCH-LIST, MEDIUM confidence. For a 20yo MMA athlete with brain-priority frame, modest anxiety baseline, chronotype migration in progress, and unknown CYP2D6 phenotype — yohimbine is a tool for a narrow situational job (fasted-cardio stubborn-fat mobilization in already-lean lifters) that this user does not currently need. Fat-loss case is weak at <12% BF; anxiety + sleep + CV costs are real; CYP2D6 unknown means dose-titration is blind. Verdict reopens narrowly for a specific contest cut + CYP2D6 EM result + zero stacked stims + low-anxiety baseline confirmed. The Charney 1984 panic-challenge mechanism is the load-bearing safety concern.
▸ Open questions / gaps Open
  1. CYP2D6 phenotype awaiting 23andMe (June 2026). Single most actionable pre-test data point. PM phenotype would push verdict to AVOID even for narrow use cases.
  2. Personal anxiety baseline characterization. A 5 mg test dose, fasted AM, before any cardio session, would characterize personal response — but probably not worth doing without a use case in mind.
  3. Lipolysis biomarker tracking. Free fatty acids + glycerol pre/post-dose would directly verify the lipolytic mechanism in this user — but bloodwork cadence makes this impractical.
  4. CYP2D6 inhibitor exposure check. Is the user on or planning to start any CYP2D6 inhibitor (bupropion, fluoxetine, paroxetine)? If yes, yohimbine is essentially contraindicated.
  5. Whether stubborn-fat depot mobilization is even a goal. Body-comp goals at 20yo MMA athlete should be frame-relative — "looks like a fighter" is mostly about lean mass + skill + conditioning, not last-3% mobilization. The use case for yohimbine is largely cosmetic in this archetype.
  6. Long-term CV load in repeated short-cycle users. Almost no data. Most yohimbine RCTs are 3-6 weeks. Annual cumulative dosing pattern unknown.

References

Galitzky et al. 1988 — Effect of yohimbine on adrenergic-mediated lipolysis (PMID 2899551)

pubmed.ncbi.nlm.nih.gov · 1988

foundational fat-cell α2-blockade lipolysis study.

View Study

Charney, Heninger, Breier 1984 — Noradrenergic function in panic anxiety: yohimbine effects (Arch Gen Psychiatry, PMID 6324726)

pubmed.ncbi.nlm.nih.gov · 1984

landmark panic-provocation paper.

View Study

McCarty 2002 — Pre-exercise yohimbine for fat-loss mechanism (Med Hypotheses, PMID 11859876)

pubmed.ncbi.nlm.nih.gov · 2002

fasted-state requirement framework.

View Study

Kearney et al. 2010 — Yohimbine in ED systematic review (PMID 20718941)

pubmed.ncbi.nlm.nih.gov · 2010

modern ED meta-analysis.

View Study

Ernst & Pittler 1998 — Yohimbine in ED meta-analysis (J Urol, PMID 9494135)

pubmed.ncbi.nlm.nih.gov · 1998

pre-Viagra meta of 7 RCTs.

View Study

Yohimbine - StatPearls (NCBI Bookshelf)

ncbi.nlm.nih.gov

clinical reference.

View Source

WADA Prohibited List 2026

wada-ama.org · 2026

yohimbine confirmed not on prohibited list.

View Source

Yohimbine - Wikipedia 2026

en.wikipedia.org · 2026

overview, history, regulatory status.

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…